NovaBay Pharmaceuticals (NYSE:NBY) Research Coverage Started at StockNews.com

Analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Performance

Shares of NovaBay Pharmaceuticals stock opened at $0.47 on Friday. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $19.57. The stock has a market capitalization of $2.32 million, a P/E ratio of 0.00 and a beta of 0.73. The business’s fifty day moving average price is $0.96 and its 200 day moving average price is $2.65.

NovaBay Pharmaceuticals (NYSE:NBY) last issued its earnings results on Tuesday, August 13th. The company reported ($1.37) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative net margin of 91.86% and a negative return on equity of 744.33%. The firm had revenue of $2.40 million during the quarter. As a group, sell-side analysts predict that NovaBay Pharmaceuticals will post -0.17 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NovaBay Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 718,768 shares of the company’s stock, valued at approximately $147,000. Armistice Capital LLC owned approximately 11.01% of NovaBay Pharmaceuticals at the end of the most recent reporting period. 23.25% of the stock is currently owned by institutional investors.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.